Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/HSPA5_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/HSPA5_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HSPA5_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HSPA5_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HSPA5_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HSPA5_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/HSPA5_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HSPA5_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/HSPA5_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HSPA5_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HSPA5_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/HSPA5_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HSPA5_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0042698 | Endometrium | AEH | ovulation cycle | 18/2100 | 68/18723 | 3.77e-04 | 4.07e-03 | 18 |
GO:00313468 | Endometrium | AEH | positive regulation of cell projection organization | 61/2100 | 353/18723 | 3.91e-04 | 4.20e-03 | 61 |
GO:004362016 | Endometrium | AEH | regulation of DNA-templated transcription in response to stress | 15/2100 | 53/18723 | 5.25e-04 | 5.31e-03 | 15 |
GO:00071796 | Endometrium | AEH | transforming growth factor beta receptor signaling pathway | 38/2100 | 198/18723 | 6.41e-04 | 6.23e-03 | 38 |
GO:00466602 | Endometrium | AEH | female sex differentiation | 25/2100 | 114/18723 | 7.30e-04 | 6.99e-03 | 25 |
GO:190357315 | Endometrium | AEH | negative regulation of response to endoplasmic reticulum stress | 13/2100 | 44/18723 | 7.79e-04 | 7.36e-03 | 13 |
GO:005108510 | Endometrium | AEH | chaperone cofactor-dependent protein refolding | 11/2100 | 34/18723 | 8.45e-04 | 7.82e-03 | 11 |
GO:00092679 | Endometrium | AEH | cellular response to starvation | 31/2100 | 156/18723 | 1.08e-03 | 9.46e-03 | 31 |
GO:005159116 | Endometrium | AEH | response to cAMP | 21/2100 | 93/18723 | 1.27e-03 | 1.09e-02 | 21 |
GO:00714807 | Endometrium | AEH | cellular response to gamma radiation | 10/2100 | 31/18723 | 1.48e-03 | 1.23e-02 | 10 |
GO:004361816 | Endometrium | AEH | regulation of transcription from RNA polymerase II promoter in response to stress | 13/2100 | 47/18723 | 1.53e-03 | 1.26e-02 | 13 |
GO:00365033 | Endometrium | AEH | ERAD pathway | 23/2100 | 107/18723 | 1.55e-03 | 1.27e-02 | 23 |
GO:00316699 | Endometrium | AEH | cellular response to nutrient levels | 39/2100 | 215/18723 | 1.66e-03 | 1.36e-02 | 39 |
GO:00450475 | Endometrium | AEH | protein targeting to ER | 12/2100 | 42/18723 | 1.70e-03 | 1.37e-02 | 12 |
GO:00712149 | Endometrium | AEH | cellular response to abiotic stimulus | 55/2100 | 331/18723 | 1.85e-03 | 1.46e-02 | 55 |
GO:01040049 | Endometrium | AEH | cellular response to environmental stimulus | 55/2100 | 331/18723 | 1.85e-03 | 1.46e-02 | 55 |
GO:003166810 | Endometrium | AEH | cellular response to extracellular stimulus | 43/2100 | 246/18723 | 2.10e-03 | 1.63e-02 | 43 |
GO:00425949 | Endometrium | AEH | response to starvation | 36/2100 | 197/18723 | 2.15e-03 | 1.65e-02 | 36 |
GO:00354375 | Endometrium | AEH | maintenance of protein localization in endoplasmic reticulum | 6/2100 | 14/18723 | 2.67e-03 | 1.94e-02 | 6 |
GO:00712364 | Endometrium | AEH | cellular response to antibiotic | 6/2100 | 14/18723 | 2.67e-03 | 1.94e-02 | 6 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0414118 | Breast | Precancer | Protein processing in endoplasmic reticulum | 33/684 | 174/8465 | 2.78e-06 | 3.83e-05 | 2.94e-05 | 33 |
hsa0541718 | Breast | Precancer | Lipid and atherosclerosis | 37/684 | 215/8465 | 7.64e-06 | 9.29e-05 | 7.12e-05 | 37 |
hsa0461218 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa030609 | Breast | Precancer | Protein export | 6/684 | 23/8465 | 8.34e-03 | 4.54e-02 | 3.48e-02 | 6 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0414119 | Breast | Precancer | Protein processing in endoplasmic reticulum | 33/684 | 174/8465 | 2.78e-06 | 3.83e-05 | 2.94e-05 | 33 |
hsa0541719 | Breast | Precancer | Lipid and atherosclerosis | 37/684 | 215/8465 | 7.64e-06 | 9.29e-05 | 7.12e-05 | 37 |
hsa0461219 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa0306012 | Breast | Precancer | Protein export | 6/684 | 23/8465 | 8.34e-03 | 4.54e-02 | 3.48e-02 | 6 |
hsa0501224 | Breast | IDC | Parkinson disease | 107/867 | 266/8465 | 2.57e-39 | 8.36e-37 | 6.26e-37 | 107 |
hsa0502023 | Breast | IDC | Prion disease | 102/867 | 273/8465 | 3.70e-34 | 4.01e-32 | 3.00e-32 | 102 |
hsa0501423 | Breast | IDC | Amyotrophic lateral sclerosis | 102/867 | 364/8465 | 1.29e-22 | 5.22e-21 | 3.91e-21 | 102 |
hsa0502223 | Breast | IDC | Pathways of neurodegeneration - multiple diseases | 116/867 | 476/8465 | 3.63e-20 | 1.18e-18 | 8.82e-19 | 116 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HSPA5 | SNV | Missense_Mutation | | c.887N>C | p.Lys296Thr | p.K296T | P11021 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-A8-A08Z-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HSPA5 | SNV | Missense_Mutation | | c.211N>A | p.Glu71Lys | p.E71K | P11021 | protein_coding | deleterious_low_confidence(0.03) | benign(0.02) | TCGA-AC-A2B8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | chemo | PD |
HSPA5 | SNV | Missense_Mutation | novel | c.414N>T | p.Lys138Asn | p.K138N | P11021 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.902) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HSPA5 | SNV | Missense_Mutation | rs368840257 | c.1595G>A | p.Arg532His | p.R532H | P11021 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.956) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HSPA5 | SNV | Missense_Mutation | | c.1540N>C | p.Glu514Gln | p.E514Q | P11021 | protein_coding | tolerated_low_confidence(0.24) | probably_damaging(0.982) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
HSPA5 | SNV | Missense_Mutation | rs191087735 | c.395N>C | p.Ile132Thr | p.I132T | P11021 | protein_coding | tolerated_low_confidence(0.13) | benign(0.012) | TCGA-E2-A56Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
HSPA5 | SNV | Missense_Mutation | novel | c.433N>G | p.Ile145Val | p.I145V | P11021 | protein_coding | tolerated_low_confidence(0.38) | benign(0.011) | TCGA-S3-AA12-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
HSPA5 | SNV | Missense_Mutation | rs762582529 | c.971N>A | p.Arg324Gln | p.R324Q | P11021 | protein_coding | deleterious_low_confidence(0.03) | benign(0.368) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HSPA5 | SNV | Missense_Mutation | | c.1712N>A | p.Ser571Tyr | p.S571Y | P11021 | protein_coding | tolerated_low_confidence(0.05) | benign(0.114) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
HSPA5 | SNV | Missense_Mutation | novel | c.949N>T | p.Asp317Tyr | p.D317Y | P11021 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | STROBOPININ | STROBOPININ | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | TCMDC-123749 | CHEMBL524376 | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | NORGESTREL | NORGESTREL | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | MIANSERIN | MIANSERIN | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | AG-490 | CHEMBL56543 | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | CHLORQUINALDOL | CHLORQUINALDOL | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | SAM-6 | | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | 5-NITRO-2-PHENYLPROPYLAMINOBENZOIC ACID [NPPB] | 5-NITRO-2-PHENYLPROPYLAMINOBENZOIC ACID [NPPB] | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | THAPSIGARGIN | THAPSIGARGIN | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | NKP-1339 | IT-139 | |